



Colombia Médica
ISSN: 0120-8322
ISSN: 1657-9534
Universidad del Valle

Para-Lara, Luis Gabriel; Arango-Ibañez, Juan Pablo; Martínez-Arboleda, Juan J.; Bravo, Juan C.; Zambrano, Ángela R.; Collazos, Paola; Andino, Francisco; Badillo, Angélica; Estrada, Sebastián; Rosso, Fernando
Survival of patients living with HIV and cancer in Cali, Colombia
Colombia Médica, vol. 54, no. 3, e2015558, 2023, July-September
Universidad del Valle

DOI: <https://doi.org/10.25100/cm.v54i3.5588>

Available in: <https://www.redalyc.org/articulo.oa?id=28376255004>

- ▶ How to cite
- ▶ Complete issue
- ▶ More information about this article
- ▶ Journal's webpage in redalyc.org



Scientific Information System Redalyc

Network of Scientific Journals from Latin America and the Caribbean, Spain and Portugal

Project academic non-profit, developed under the open access initiative

Survival of patients living with HIV and cancer in Cali, Colombia

Supervivencia de pacientes con VIH y Cáncer en Cali, Colombia



English Version



Spanish version

Luis Gabriel Parra-Lara^{1,2}  Juan Pablo Arango-Ibañez¹  Juan J. Martínez-Arboleda²  Juan C. Bravo³  Ángela R. Zambrano⁴  Paola Collazos⁵  Francisco Andino⁶  Angélica Badillo²  Sebastián Estrada²  Fernando Rosso^{1,2,7} 

1 Universidad Icesi, Facultad de Ciencias de la Salud, Cali, Colombia. 2 Fundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Cali, Colombia. 3 Fundación Valle del Lili, Departamento de Patología y Laboratorio Clínico, Cali, Colombia. 4 Fundación Valle del Lili, Departamento de Medicina Interna, Servicio de Hematología & Oncología Clínica, Cali, Colombia. 5 Universidad del Valle, Facultad de Salud, Registro Poblacional de Cáncer de Cali (RPCC), Cali, Colombia. 6 Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador. 7 Fundación Valle del Lili, Departamento de Medicina Interna, Servicio de Infectología, Cali, Colombia.



Citation: Parra-Lara LG, Arango-Ibañez JP, Martínez-Arboleda JJ, Bravo JC, Zambrano AR, Collazos P, Andino F, Badillo A, Estrada S, Rosso F. **Survival of patients living with HIV and cancer in Cali, Colombia.** *Colomb Méd (Cali)*,2023; 54(3):e2015558. <http://doi.org/10.25100/cm.v54i3.5558>

Received: 13 mar 2023

Revised: 22 ago 2023

Accepted: 21 sep 2023

Published: 30 sep 2023

Keywords:

Antiretroviral Therapy; Acquired Immuno-deficiency Syndrome; Sarcoma Kaposi; Uterine Cervical Neoplasms; Lymphoma Non-Hodgkin; HIV Infections; Oncogenic Viruses; Coinfection; Carcinoma Squamous Cell; Tuberculosis.

Palabras clave:

Terapia Antirretroviral; Síndrome de Inmunodeficiencia Adquirida; Sarcoma de Kaposi; Neoplasias del Cuello Uterino; Linfoma No Hodgkin; Infecciones por VIH; Virus Oncogénicos; Coinfección; Carcinoma de Células Escamosas; Tuberculosis.hematopoyéticos.

Abstract

Background:

People living with HIV have an increased risk of cancer compared to the general population. However, with the increase in life expectancy and advances in antiretroviral therapy, the survival of patients with cancer and HIV has changed.

Objective:

To determine the survival of patients living with HIV and cancer in Cali, Colombia.

Methods:

A retrospective cohort study was conducted at the Fundación Valle del Lili, Cali, Colombia. Data from the HIV database was crossed with data from the hospital and population-based cancer registries between 2011-2019. Patients <18 years, limited available clinical information on the diagnosis and treatment of HIV and cancer, and non-oncological tumor diagnosis were excluded.

Results:

A total of 173 patients were included. The frequencies of AIDS-defining neoplasms were: Non-Hodgkin lymphoma (42.8%), Kaposi sarcoma (27.8%), and cervical cancer (4.6%). Overall survival was 76.4% (95% CI 68.9-82.3) at five years. Poorer survival was found in patients with AIDS-defining infections (56.9% vs. 77.8%, $p=0.027$) and non-AIDS-defining infections (57.8% vs. 84.2%, $p=0.013$), while there was better survival in patients who received antiretroviral therapy (65.9% vs. 17.9%, $p=0.021$) and oncological treatment (66.7% vs. 35.4%, $p<0.001$). The presence of non-AIDS-defining infections increases the risk of dying (HR = 2.39, 95% CI 1.05-5.46, $p=0.038$), while oncological treatment decreases it (HR = 0.33, 95% CI 0.14-0.80, $p=0.014$).

Copyright: © 2023 Universidad del Valle



Conflict of interest:

All authors have declared no conflicts of interest

Funding: None

Acknowledgements:

We thank the Centro de Investigaciones Clínicas (CIC) at Fundación Valle del Lili and RPCC staff at Universidad del Valle, especially Prof. Luis Eduardo Bravo and Luz Stella García, for their support in this manuscript

Corresponding author:

Luis Gabriel Parra-Lara. MD, Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, Colombia. Email: luis.parra5@u.icesi.edu.co ; Luis.parra@fvl.org.co

Conclusions:

In people living with HIV, Non-Hodgkin lymphoma and Kaposi sarcoma are the most common neoplasms. Factors such as AIDS-associated and non-AIDS-associated infections have been identified as determinants of survival. Cancer treatment seems to improve survival

Resumen

Antecedentes:

Las personas que viven con VIH tienen un riesgo mayor de cáncer en comparación con la población general. Sin embargo, con el aumento de la esperanza de vida y los avances en la terapia antirretroviral, la supervivencia de los pacientes con cáncer y VIH ha cambiado.

Objetivo:

Determinar la supervivencia de los pacientes que viven con VIH y cáncer en Cali, Colombia.

Métodos:

Se realizó un estudio de cohorte retrospectivo en la Fundación Valle del Lili, Cali, Colombia. Los datos de la base de datos de VIH se cruzaron con los datos de los registros de cáncer de base hospitalaria y poblacional entre 2011-2019. Se excluyeron los pacientes <18 años, con información clínica limitada disponible sobre el diagnóstico y tratamiento del VIH y el cáncer y los casos con diagnóstico de tumor no oncológico.

Resultados:

Se incluyeron un total de 173 pacientes. Las frecuencias de neoplasias definitivas de SIDA fueron: linfoma no Hodgkin (42.8%), sarcoma de Kaposi (27.8%) y cáncer cervical (4.6%). La supervivencia global fue del 76.4% (IC 95% 68.9-82.3) a los cinco años. Se encontró una peor supervivencia en pacientes con infecciones definitivas de SIDA (56.9% vs. 77.8%, $p=0.027$) e infecciones no definitivas de SIDA (57.8% vs. 84.2%, $p=0.013$), mientras que hubo una mejor supervivencia en pacientes que recibieron terapia antirretroviral (65.9% vs. 17.9%, $p=0.021$) y tratamiento oncológico (66.7% vs. 35.4%, $p<0.001$). La presencia de infecciones no definitivas de SIDA aumentó el riesgo de morir (HR = 2.39, IC 95% 1.05-5.46, $p=0.038$), mientras que el tratamiento oncológico lo disminuyó (HR = 0.33, IC 95% 0.14-0.80, $p=0.014$).

Conclusiones:

En las personas que viven con VIH, el linfoma no Hodgkin y el sarcoma de Kaposi son las neoplasias más comunes. Se han identificado factores como las infecciones asociadas al SIDA y las infecciones no asociadas al SIDA como determinantes de la supervivencia. El tratamiento del cáncer parece mejorar la supervivencia.

Remark

1) ¿Why was this study conducted?

To describe factor associated with survival of patients living with HIV and cancer in Cali, Colombia.

2) ¿What were the most relevant results of the study?

Antiretroviral therapy and oncological treatment were associated with increased survival, and poorer prognosis was seen in patients with AIDS-defining infections and non-AIDS-defining infections.

3) ¿What do these results contribute?

These results assert the relevance of both antiretroviral and oncological treatment in the prognosis of patients with HIV and cancer, and reaffirm the importance of decreasing the rate of infections in these patients to improve survival.

Introduction

In Colombia, the first case of AIDS was reported in 1984, three years after the first reports of the disease in 1981^{1,2}. According to UNAIDS, it is estimated that 200,000 [160,000 - 250,000] people of all ages with an HIV diagnosis live in Colombia, and 12,000 [8,400 - 20,000] new cases are diagnosed annually, for an incidence of 0.40 [0.26. - 0.61] per-100,000 inhabitants³.

Various studies have shown that people living with HIV have a higher risk of cancer, including Hodgkin lymphoma, anal cancer, lung cancer, liver cancer and certain skin cancers, than the general population^{4,5}. With the emergence of combined highly active antiretroviral therapy (HAART), morbidity and mortality from HIV-related diseases, including Kaposi sarcoma and non-Hodgkin lymphoma, have been drastically reduced⁶⁻⁸. However, morbidity and mortality from other types of cancer, such as anal, cervical, lung and oropharyngeal cancer and Hodgkin lymphoma, have remained high despite HAART^{9,10}.

According to an analysis of the HIV/AIDS situation in Colombia, non-AIDS-related neoplasms occurred in 0.74% of people living with HIV, while the frequency of AIDS-defining neoplasms were as follows: Kaposi sarcoma (1.76%), Burkitt lymphoma (0.34%) and invasive cervical cancer (0.14%)¹¹. This is comparable to estimates made in other parts of the world^{5,12-15}.

These estimates are made from different sources of information that are part of the country's Public Health Surveillance System¹⁶. This system includes data on patients diagnosed with HIV and cancer^{17,18}. Nevertheless, there are other globally recognized sources of high-quality information, such as cancer registries, which collect, store, analyze and interpret data on new cases of cancer within a specific population and for a specific period and consequently allow estimates of the incidence, survival and mortality of cancer to be made¹⁹. Therefore, there is a need to use high-quality and continuously collected information to understand cancer in people living with HIV. This study aimed to determine the survival of people with HIV and cancer.

Materials and Methods

Design and setting

A retrospective, hospital-based, observational cohort study was conducted in Cali, Colombia. Cali, the capital of the Valle del Cauca Province, is the third city in the country, with around 2,250,000 inhabitants in 2019²⁰. The network for cancer care has 165 authorized oncology services located in the urban area, where 95% of the population²¹. During the five-year period 2013-2017, 24,963 new cancer cases were diagnosed in permanent residents of Cali, with an age-standardized incidence rate for all locations in men of 191.2 and 175.4 in women²².

Fundación Valle del Lili is a high-complexity university hospital serving as a southwestern Colombia reference center. It is one of the five hospitals that has integrated oncological services in the city, with a hospital-based cancer registry (HBCR) that includes data related to patient identification, cancer identification, the first course of treatment and outcomes. The case definition and registry methodology have been previously described²³. Data extraction was done by active search and continuous.

Patients and follow-up

HIV cases. Cases were obtained from the hospital HIV database from 2011-2019. This database included all people living with HIV treated in our hospital independent of time and place of diagnosis, disease stage, degree of immunosuppression or if they died during the observation time. Confirmatory tests for the diagnosis of HIV that are established in the “clinical practice guideline recommendations for the care of HIV/AIDS infection in adults, pregnant and adolescents” by the Colombian Ministry of Health were verified²⁴. The patient was found to have two positive ELISA tests or two positive rapid tests, or a viral load above 5,000 copies/mL, or a positive Western Blot test. HIV cases are reported to the public health surveillance system database. The database includes information related to insurance, risk management and the impact of the disease^{17,25}.

Cancer cases

Cases were obtained from the Registro Poblacional de Cáncer de Cali (RPCC) database and HBCR from both sexes and all ages and localizations.

The RPCC is a population-based cancer registry that has operated continuously since 1962. It includes the new cancer cases through notification and active searching in primary data sources, including hospitals, clinics, pathology laboratories, and cancer centers. Then, it integrates the data into the database following the international standards of good practice. The RPCC has good information quality indicators, and its methodology has been previously presented^{26,27}.

Cases were men and women with a diagnosis of neoplasm (all localizations) codified according to the Classification of Diseases for Oncology 3rd edition (ICD-O-3)²⁸, no matter if it was confirmed or partially or fully treated. The basis for the diagnosis can be microscopic (fluid cytology, bone marrow, histology of a primary tumor and autopsy) and non-microscopic (clinical, surgical, and imaging diagnosis).

The Centers for Disease Control and Prevention (CDC) definitions of AIDS-defining neoplasms and AIDS-defining infections were considered²⁹. The oncological treatment variable included any medical-surgical intervention provided for cancer management.

Matching. The HIV cases database was matched with cancer cases databases (RPCC and HBCR). All neoplasms identified by the RPCC and HBCR were included.

Exclusion criteria. Patients under 18 years of age at the time of HIV diagnosis, limited available clinical information on the diagnosis and treatment of HIV and cancer and non-oncological tumor diagnosis were excluded.

Follow-up. Vital status and the date of death or the last follow-up day were determined using the cancer databases (RPCC or HBCR), general hospital mortality, hospital discharge, or the health system affiliation database (BDUA).

Data

All cases were characterized based on the information in the medical records, the HBCR and the RPCC databases. It includes the IARC/WHO International Classification of Diseases for Oncology, third revision classification (ICDO-3), the age at diagnosis, location/topography, morphology and follow-up (last contact and vital status) of all patients.

The duplicate cases in all sources of registries were identified and removed. Some characteristics such as identification, date of birth, health insurance regime, residence, ICD-O-3 code related to their cancer type and vital status were used to identify the common cases among databases.

A comparison was made in the proportions of HIV and cancer cases with the total cancer patients reported by the High-Cost Diseases Office report (period 2014-2018) and the RPCC (period 2014-2020).

Ethical considerations

The Comité de Ética en Investigación Biomédica of the Fundación Valle del Lili approved the study protocol following the ethical principles of medical research described in the Declaration of Helsinki and considering the regulations of Resolution 8430/1993 of the Ministry of Health and Social Protection of Colombia.

Statistical analysis

A descriptive analysis of the sociodemographic and clinical variables was performed using central tendency and dispersion measures.

Survival analysis was performed using the Kaplan-Meier method. Survival was calculated using the date of cancer diagnosis and the date of death or the last day of follow-up (the last day of hospital care and the date of last contact recorded; the most recent date was used). Random censoring was performed for cases that did not complete 5 years of follow-up. Overall survival for 12, 36 and 60 months of follow-up was calculated. The differences were evaluated using the log-rank test. A Cox regression was performed to evaluate the factors associated with survival. The assumption of proportionality was verified by specific tests of the model and Cox-Snell residuals.

A value of $p < 0.05$ was considered statistically significant. All analyses were performed using STATA® (Version 14.0, StataCorp LP, College Station, TX).

Results

A total of 2,590 cases were reported in the hospital HIV database for the period 2011-2019; there were 463 duplicate records. Then, 245 patients were identified by matching the HIV and, RPCC and HBCR databases. After fulfilling the selection criteria, 72 patients were excluded due to incomplete information ($n = 64$), age younger than 18 years ($n = 5$) or the presence of a non-oncological tumor ($n = 3$). A total of 173 patients with HIV and cancer were included in the study.

Description of the cases

The demographic and clinical characteristics of the patients are presented in Table 1. The minimum age was 19, and the maximum age was 99 years. A total of 84.4% were male.

Thirty-three patients had a diagnosis of cancer prior to 2011. In most cases, the cancer occurred prior to the diagnosis of HIV (61.9%), while in 93% of cases, the cancer occurred

Table 1. Demographic and clinical characteristics of the included patients (n= 173).

Characteristics	n (%)
Male sex	146 (84.4)
Age (years), Me (IQR)	43 (33-52)
Residence in Cali	113 (65.3)
Cancer diagnosis year	
1999-2005	7 (4.1)
2006-2010	26 (15.0)
2011-2015	99 (57.2)
2016-2018	41 (23.7)
Time of onset of cancer since HIV diagnosis	
Prior to diagnosis	107 (61.9)
Post diagnosis	
0-2 months	39 (22.5)
2-12 months	11 (6.4)
>12 months	16 (9.3)
Hepatitis B	8 (4.6)
Hepatitis C	3 (1.7)
AIDS-defining neoplasms	
Non-Hodgkin lymphoma	74 (42.8)
Kaposi sarcoma	48 (27.8)
Cervical cancer	8 (4.6)
Oncological treatment	143 (88.8)
AIDS-associated infection	108 (68.8)
Non-AIDS-associated infection	113 (73.4)
Palliative care	25 (16.6)
Vital status	
Alive	109 (63.0)
Dead	64 (37.0)

one year after the HIV diagnosis. Regarding AIDS-defining neoplasms, the most common was Non-Hodgkin lymphoma (42.8%), followed by Kaposi sarcoma (27.8%) and cervical cancer (4.6%). The most common locations of other neoplasms (not related to AIDS) were the anus, anal canal (6.4%) and prostate (3.5%) (Figure S1, Supplementary file).

A total of 88.8% of the patients had undergone some cancer treatment: chemotherapy (n = 114), surgery (n= 31) or radiotherapy (n= 29). A total of 16.6% had at least one assessment for palliative care during their hospital stay. A total of 68.8% had an AIDS-defining infection. A total of 37.0% of the patients died during the follow-up period.

Comparison of cases

Table 2 shows the proportion of cases in our study (HIV and cancer) compared to the total number of cancer cases reported by the High-Cost Diseases Office report and the RPCC. A higher proportion of AIDS-defining neoplasms was observed in the FVL group for non-Hodgkin lymphoma and Kaposi sarcoma, while a higher proportion of cervical cancer was observed in the RPCC database.

Table 2. Comparison of Fundación Valle del Lili cancer cases, High-Cost Fund Report and RPCC.

Type of neoplasms	HBCR* n=173		RPCC† n=56,419						CAC‡ n=24,405					
			Cali		Other Cities		Total		Cali		Other Cities		Total	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
AIDS-defining neoplasms	130	75.1	3,349	9.2	2,036	10.2	5,385	9.5	961	6.3	717	7.8	1,678	6.9
Non-Hodgkin lymphoma	74	42.8	1,737	4.8	802	4.0	2,539	4.5	518	3.4	336	3.7	854	3.5
Kaposi sarcoma	48	27.8	109	0.3	37	0.2	146	0.3	36	0.2	14	0.2	50	0.2
Cervical cancer	8	4.6	1,503	4.1	1,197	6.0	2,700	4.8	407	2.7	367	4.0	774	3.2
Other neoplasms	43	24.9	33,152	90.8	17,882	89.8	51,034	90.5	14,302	93.7	8,425	92.2	22,727	93.1

*HIV and cancer cases, period 2011-2019.

†Population-based cancer registry, period 2014-2020.

‡High-Cost Diseases Office, period 2014-2018




Figure 1. Kaplan-Meier estimate for the overall survival of the included patients.

Survival analysis

The median follow-up was 3.1 years (IQR= 0.4-7.2 years). Overall survival was 76.4% (95% CI 68.9-82.3) at one year and 64.3% (95% CI: 55.7-71.6) at five years (Figure 1). Significant differences were found for the use of antiretroviral therapy ($p= 0.021$), AIDS-defining infections ($p = 0.027$), non-AIDS-defining infections ($p= 0.013$) and oncological treatment ($p <0.001$) (Table 3).

Cox regression model that included the diagnosis of AIDS-defining infections, Non-AIDS-defining infections and oncological treatment showed that infections decreased survival (HR= 2.39, 95% CI= 1.05-5.46), while oncological treatment increased it (HR= 0.33, 95% CI= 0.14-0.80) (Table 4).

Discussion

This study presents survival findings for a cohort of people living with HIV and cancer from Cali, Colombia, during the HAART era. The findings show that AIDS-defining neoplasms (Non-Hodgkin lymphoma, Kaposi sarcoma and invasive cervical cancer) are the most frequently occurring types of cancer, followed by anal cancer, despite significant advances in the early diagnosis and treatment of HIV. Cancer treatment was found to significantly impact survival, while AIDS-defining infections contribute significantly to adverse outcomes of HIV.

Although the relationship between HIV and the occurrence of certain types of cancer is not fully understood, it has been associated with factors such as net immunity status (immunosuppression) and exposure to non-intrinsic exposure risk factors (coinfection with oncogenic viruses and lifestyle factors). This was reflected mainly by the frequency of alcohol and cigarette consumption and the frequency of AIDS-defining infections that characterize the advanced phase of HIV infection.

Non-Hodgkin lymphoma and Kaposi sarcoma are the most common neoplasms in patients with HIV³⁰⁻³³. A study conducted between 2007 and 2014 at the National Cancer Institute in Bogotá DC that included 139 patients found that AIDS-defining neoplasms were present in 65.5% of cases; the most frequent were Non-Hodgkin lymphoma (n= 46), followed by Kaposi sarcoma (n = 42)³⁴. On

Table 3. Survival of patients with cancer and HIV in Cali, Colombia, period 2011-2019.

Variable	Estimated five-year survival (95% CI)*
Sex	
Male	61.7 (52.3-69.7)
Female	77.8 (50.4-91.2)
Age	
<30	72.0 (47.6-86.4)
30-39	59.3 (40.7-73.9)
40-49	66.8 (50.4-78.9)
≥50	62.2 (46.3-74.6)
Residence	
Cali	64.5 (54.8-73.4)
Another municipality	65.2 (49.1-77.3)
Antiretroviral therapy	65.9 (56.4-73.8)
AIDS-defining malignancies	62.3 (51.4-71.4)
AIDS-defining infections	56.9 (45.7-66.6)
Non-AIDS-defining infections	57.8 (46.7-67.4)
Oncological treatment‡	66.7 (57.4-74.4)

*Kaplan-Meier method

‡ No data (n = 6)

Table 4. Proportional hazards model in patients with cancer and HIV in Cali, Colombia, period 2011-2019.

Variable	HR (95% CI)
AIDS-defining infections	1.77 (0.87-3.62)
Non-AIDS-defining infections	2.39 (1.05-5.46)*
Oncological treatment	0.33 (0.14-0.80)*

* $p < 0.05$

the other hand, a study conducted in Cali described the incidence of these neoplasms before and during the HIV/AIDS epidemic (between 1962 and 2010) and found an association between the decrease in the incidence of Kaposi sarcoma in men and the introduction of HAART in Colombia starting in the year 2004³⁵. These findings show that AIDS-defining neoplasms are in decline due to advances in HAART and promotion and prevention strategies.

It is striking that the study, published by the public health surveillance system database in 2017, found a total of 736 cases of people living with HIV and cancer between 1983 and 2015 in the country, and of these, 35 cases (29 men and six women) were in the department of Valle del Cauca. The study was limited to neoplasms diagnosed between 60 months before and any date after the diagnosis of AIDS³⁶. It is very worrying that the public health surveillance system underestimates HIV-associated neoplasms (possibly due to limited sample size) because our study found at least 173 patients with these conditions during a shorter observation period and at a single hospital. This discrepancy shows an underreporting of people living with HIV and cancer, affecting public health decision-making and moving us away from the Sustainable Development Goals for HIV/AIDS. Similarly, it justifies the importance of cancer registries (population-based cancer registry and HBCR) as quality information sources for cancer.

Invasive cervical cancer was present in a low proportion in our cohort and can be explained by the lower proportion of women with HIV in the study population, which was also observed in the public health surveillance system report for this region¹¹. While cervical cancer continues to be the leading cause of cancer mortality in Colombia and the second leading type of cancer among women³⁷, it is possible that advances in primary prevention (prophylactic vaccines against HPV) and secondary prevention (early detection of cervical cancer with cervical cytology and DNA-HPV testing) and the strengthening of prevention and promotion programs through the implementation of clinical practice guidelines for early detection have had an impact on the burden of this disease in recent years.

Squamous cell carcinoma of the anus was the most common non-AIDS-defining neoplasm and had a mortality of 27%, similar to that reported in other published studies^{38,39}. This neoplasm is more prevalent among men who have sex with men (MSM) with HIV than in those who are not infected^{40,41}, and its incidence has increased in the last 30 years despite advances in HAART⁴². These factors may be related to the low implementation of screening strategies for anal dysplasia in clinical practice⁴³⁻⁴⁶, although it has been shown that anal HPV cytology has a positive impact on the reduction of anal cancer in MSM⁴⁷. Another factor to consider is the low vaccination rate in the male population⁴⁸.

The overall survival at five years was 64%. Previous estimates for people living with HIV with AIDS-defining neoplasms range from 50-80%⁴⁹⁻⁵¹, and some estimates are higher than 90%⁵². This is due to factors such as the human development index, access to the health system, neoplasia type, and the time since HIV diagnosis. In the patients in this cohort, a possible related factor was a delay in diagnosis of HIV, since 62% were diagnosed first with cancer and then with HIV. HIV preceded by a cancer diagnosis is a known predictor of mortality⁵², a situation that has also been reported in Bogotá DC³⁴.

The age-adjusted mortality in Colombia was 3.31 (95% CI 3.15-3.47) per 100,000 inhabitants, and the lethality was 13.17 per 1,000 in people living with HIV¹¹. Our study found no differences in survival between AIDS-defining and non-AIDS-defining neoplasms. Similar findings have been previously reported in Latin America, where patients with non-AIDS-defining neoplasms had survival probabilities that were equivalent to those with AIDS-defining neoplasms at one year of follow-up (81% vs. 79%) and were notably lower at five years of follow-up (60% vs. 69%). However, there were no significant differences ($p=0.18$)⁵³. The survival rate found in this study was similar to that reported for other countries^{54,55}.

One factor associated with decreased survival was the diagnosis of AIDS-defining infections. Among the most prevalent opportunistic infections are *Pneumocystis jirovecii* (PCP), tuberculosis and toxoplasmosis^{49,56,57}. These infections are the main causes of mortality and admission to the intensive care unit in patients with HIV, despite advances in treatment⁵⁷. Therefore, the early and adequate initiation of HAART is relevant in this population, as is prophylaxis when the CD4+ lymphocyte count is less than 200 cells/mm³, a strategy implemented since 1989 and has improved survival^{55,58}. Similarly, close follow-up is necessary to control different risk factors in these patients, given that they have an immunocompromise profile different from that of the general population, and opportunistic infections can be present in as many as 70% of patients who die of HIV⁴⁹.

Regarding oncological treatment, it has been reported that the survival of patients with HIV and neoplasms is low, even when they receive oncospecific management^{51,59}. Although we found that oncological management was associated with better survival (HR= 0.32), management can be affected by several factors, such as the type of cancer and its location, the clinical stage at the time of diagnosis, secondary involvement, the type of treatment (surgery, systemic therapy, radiotherapy) and the presence of other associated comorbidities, which presents a challenge for professionals who care for people living with HIV and cancer.

Limitations

The study had several limitations, many of which resulted from its design. First, as a retrospective cohort study, it included data obtained from secondary data sources (medical records and health system databases); consequently, information bias could be present. Second, the study was conducted at a single health center in the city; therefore, it is not representative of the region. Finally, attempts to evaluate the impact of the presence or absence of cancer treatment on survival could be confounded by changes that occurred during follow-up, such as changes in the type of treatment, prescriptions and treatment approaches for cancer and changes in the patient's comorbidities. The situation was affected similarly by the prescription and initiation of HAART.

The strength of this study was the good quality of information regarding the description of cancer, its diagnosis and follow-up (vital status) from the RPCC and HBCR. The inclusion of this information makes this a unique study of the region.

Conclusions

Non-Hodgkin lymphoma and Kaposi sarcoma are the most common neoplasms in people living with HIV. Factors such as infections associated and not associated with AIDS have been identified as determinants of survival. Cancer treatment seems to improve survival.

References

1. Centers for Disease Control (CDC). Pneumocystis pneumonia--Los Angeles. *Morb Mortal Wkly Rep*. 1981; 30(21):250-252.
2. Instituto Nacional de Salud (INS). Comportamiento Del VIH En Colombia 2019. *Boletín Epidemiológico Semanal*. 2019; Semana epidemiológica 47: 2-3. doi:10.33610/23576189.2019.47.
3. UNAIDS. Country factsheets: Colombia 2019. UNAIDS; 2019. Accessed March 1 2023. <https://www.unaids.org/en/regionscountries/countries/colombia>.
4. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. *AIDS*. 2009;23(17):2337-2345. doi:10.1097/QAD.0b013e3283319184.
5. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. *Ann Intern Med*. 2008;148(10):728-736. doi:10.7326/0003-4819-148-10-200805200-00005.
6. Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, Di Filippo E, et al. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study. *BMC Public Health*. 2015;15(1):1-9. doi:10.1186/s12889-015-1565-0.
7. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med*. 1998;338(13):853-860. doi:10.1056/NEJM199803263381301.
8. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. *Lancet*. 2003;362(9377):22-29. doi:10.1016/s0140-6736(03)13802-0.
9. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. *Curr Opin HIV AIDS*. 2017;12(1): 6-11. DOI: 10.1097/COH.0000000000000327
10. Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti DM, Swisher-Mcclure S, et al. Reduced cancer survival among adults with HIV and AIDS-Defining illnesses despite no difference in cancer stage at diagnosis. *J Acquir Immune Defic Syndr*. 2018; 79(4):421-429. doi:10.1097/QAI.0000000000001842.
11. Cuenta de Alto Costo (CAC). Situación Del VIH/SIDA En Colombia 2020. Bogotá D.C.: Cuenta de Alto Costo (CAC); 2021.
12. Uribe PD, Pulido D, Lopes G, Sánchez QP, Acuna ML, Valencia EO. Cancer Incidence in Patients Diagnosed with Acquired Immunodeficiency Syndrome (AIDS) in Colombia. *J AIDS Clin Res*. 2017;8:5. doi:10.4172/2155-6113.1000692.
13. Kaaya EE, Castañeros-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L. AIDS and non AIDS-related malignant lymphoma in Tanzania. *Afr Health Sci*. 2006;6(2):69-75. doi:10.5555/afhs.2006.6.2.69.
14. Mbulaiteye SM, Bhatia K, Adebamowo C, Sasco AJ. HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data. *Infect Agent Cancer*. 2011;6(1):16. doi:10.1186/1750-9378-6-16.

15. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, Jacobson LP. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. *J Acquir Immune Defic Syndr*. 2008;48(4):491-499. doi:10.1097/QAI.0b013e31817aebfe.
16. Ramirez-Barbosa P, Acuña-Merchan L. Gestión del riesgo de cáncer en Colombia, 2016. *Colomb Med*. 2018;49(1):128-137. doi:10.25100/cm.v49i1.3882.
17. Ministerio de de Salud y Protección Social. Resolución 4725 de 2011. Colombia: Ministerio de Salud y Protección Social; 2011. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/Resolución_4725_de_2011.pdf.
18. Ministerio de Salud y Protección Social. Resolución 247 de 2014. Colombia: Ministerio de Salud y Protección Social; 2014:1-22. https://cuentadealtocosto.org/site/images/Resolucion_247_de_2014.PDF.
19. International Agency for Reseach on Cancer. Cancer registration: principles and methods. *IARC Sci Publ*. 1991;(95):1-288. doi:10.2307/1533655.
20. Departamento Administrativo de Planeación. Cali En Cifras 2020. Cali: Alcaldía de Cali; 2020. <http://www.cali.gov.co/planeacion/publicaciones/137803/documentos-de-cali-en-cifras/>.
21. Murcia E, Aguilera J, Wiesner C, Pardo C. Oncology services supply in Colombia. *Colomb medica (Cali, Colomb*. 2018;49(1):89-96. doi:10.25100/cm.v49i1.3620.
22. Bravo L, Garcia L, Collazos P, Carrascal E, Grillo-Ardila E, Millan E, Holguín J. Cancer epidemiology in Cali, 60 years of experience. *Colomb Med (Cali)*. 2022; 53(1): e2005050. doi:10.25100/cm.v53i1.5050.
23. Parra-Lara LG, Mendoza-Urbano DM, Zambrano ÁR, Valencia-Orozco A, Bravo-Ocaña JC, Bravo-Ocaña LE, Rosso F. Methods and implementation of a Hospital-Based Cancer Registry in a major city in a low-to middle-income country: the case of Cali, Colombia. *Cancer Causes Control*. 2022;33(3):381-392. doi:10.1007/s10552-021-01532-z.
24. Ministerio de Salud y Protección Social, Empresa Nacional Promotora del Desarrollo Territorial, Instituto de Evaluación Tecnológica en Salud. Guía de Práctica Clínica Basada En La Evidencia Científica Para La Atención de La Infección Por VIH/SIDA En Personas Adultas, Gestantes y Adolescentes. Guía Para Profesionales de La Salud. 2nd ed. Bogotá D.C.: Ministerio de Salud y Protección Social; 2021. <https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/gpc-vih-adultos-version-profesionales-salud.pdf>.
25. Cuenta de Alto Costo (CAC). Situación Del VIH Sida En Colombia 2017. Bogotá D.C: Ministerio de Salud y Protección Social; Cuenta de Alto Costo; 2018. https://cuentadealtocosto.org/site/images/Publicaciones/2018/Situacion_VIH_2017.pdf.
26. García LS, Bravo LE, Collazos P, Ramírez O, Carrascal E, Nuñez M, et al. Colombia Cali Cancer Registry Methods. *Colomb Med (Cali)*. 2018;49(491):109-120. doi:10.25100/cm.v49i1.3853.
27. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Collazos T, et al. Reliable information for cancer control in Cali, Colombia. *Colomb Med (Cali)*. 2018;49(1):23-34. doi:10.25100/cm.v49i1.3689.
28. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM. International Classification of Diseases for Oncology ICD-O-3. Geneva: World Health Organization; 2000.
29. Centers for Disease Control and Prevention (CDC). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm reports Morb Mortal Wkly report Recomm reports*. 1992;41(RR-17):1-19.
30. Clifford GM, Polesel J, Rickenbach M, Maso LD, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst*. 2005;97(6):425-432. doi:10.1093/jnci/dji072.
31. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. *AIDS*. 2006;20(12):1645-1654. doi:10.1097/01.aids.0000238411.75324.59.

32. Galceran J, Marcos-Gragera R, Soler M, Romaguera A, Ameijide A, Izquierdo Á, Borràs J, de Sanjosé S, Casabona J. Cancer incidence in AIDS patients in Catalonia, Spain. *Eur J Cancer*. 2007;43(6):1085-1091. doi:10.1016/j.ejca.2007.01.028.
33. Laurido M, Urueña A, Vizzotti C, Bugarin GCI.. Variacion de la incidencia de tumores asociados o no al sida en un centro ambulatorio, 1997-2005. *Med (Buenos Aires)*. 2007;(67):243-246.
34. Álvarez-Guevara D, Cuervo-Maldonado S, Sánchez R, Gómez-Rincón J, Ramírez N. Prevalence of defining malignancies in adult patients with HIV/AIDS in the National Cancer Institute of Colombia. 2007-2014. *Rev Fac Med*. 2017;65(3):397-402. doi:10.15446/revfacmed.v65n3.56112.
35. Saldarriaga-Cantillo A, Bravo LE, Londoño Ó, García LS, Collazos P. Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi's sarcoma in Cali, Colombia. *Colomb Médica*. 2012;43:273-280.
36. Uribe Parra D, Pulido D, Lopes G, Sanchez Martinez P, Acuña Merchan L, Valencia Estupinan O, Soler L, Gonzalez J. Cancer Incidence in Patients Diagnosed with Acquired Immunodeficiency Syndrome (AIDS) in Colombia. *J AIDS Clin Res*. 2017;08(05):1-5. doi:10.4172/2155-6113.1000692.
37. Muñoz N, Bravo LE. Epidemiology of cervical cancer in Colombia. *Colomb Med (Cali)*. 2012; 43(4): 298-304.
38. Chiu CG, Smith D, Salters KA, Zhang W, Kanters S, Milan D, Montaner JSG, Coldman A, Hogg RS, Wiseman SM. Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development. *BMC Cancer*. 2017;17(1):1-9. doi:10.1186/s12885-017-3229-1.
39. Cornejo-Juárez P, Cavildo-Jerónimo D, Volkow-Fernández P. Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico. *AIDS Res Ther*. 2018;15(1):1-9. doi:10.1186/s12981-018-0202-2.
40. Melbye M, Coté TR, Biggar RJ, Kessler L, Gail M, AIDS:Cancer Working Group. High incidence of anal cancer among AIDS patients. *Lancet*. 1994;343(8898):636-639. doi:10.1016/S0140-6736(94)92636-0.
41. Goedert JJ, Coté TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, Jaffe ES, Biggar RJ. Spectrum of AIDS-associated malignant disorders. *Lancet*. 1998;351(9119):1833-1839. doi:10.1016/S0140-6736(97)09028-4.
42. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: The Surveillance, epidemiology, and end results experience, 1973-2000. *Cancer*. 2004;101(2):281-288. doi:10.1002/cncr.20364.
43. Krishnan A, Levine AM. Malignancies in women with HIV infection. *Women's Heal*. 2008;4(4):357-368. doi:10.2217/17455057.4.4.357.
44. OPS. Estrategia y Plan de Acción Regional Para La Prevención y El Control Del Cáncer Cervicouterino En América Latina y El Caribe. Organización Panamericana de la Salud; 2008.
45. Ferenczy A, Coutlée F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: A review of recent developments. *CMAJ*. 2003;169(5):431-434.
46. Palefsky J. Human papillomavirus infection in HIV-infected persons. *Top HIV Med*. 2007;15(4):130-133.
47. Revollo B, Videla S, Libre JM, Paredes R, Piñol M, García-Cuyàs F, Omelas A, Puig J, Parés D, Corral J, Clotet B, Sirera G. Routine screening of anal cytology in persons with human immunodeficiency virus and the impact on invasive anal cancer: A prospective cohort study. *Clin Infect Dis*. 2020;71(2):390-399. doi:10.1093/cid/ciz831.
48. Gargano JW, Unger ER, Liu G, Steinau M, Meites E, Dunne E, Markowitz LE. Prevalence of genital human papillomavirus in males, United States, 2013-2014. *J Infect Dis*. 2017; 215:1070-1079. doi:10.1093/infdis/jix057.
49. Djawe K, Buchacz K, Hsu L, Chen MJ, Selik RM, Rose C, Williams T, Brooks JT, Schwarcz S. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons - San Francisco, 1981-2012. *J Infect Dis*. 2015; 212:1366-1375. doi:10.1093/infdis/jiv235.

50. Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM, Passaris I, et al. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. *J Acquir Immune Defic Syndr*. 2002;29(4):388-395. doi:10.1097/00126334-200204010-00010.
51. Mocroft A, Sterne JAC, Egger M, May M, Grabar S, Furrer H, et al. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. *Clin Infect Dis*. 2009;48(8):1138-1151. doi:10.1086/597468.
52. Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, Burns F, Copas A, Brown AE, Sullivan AK, Delpech V. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. *Lancet Public Heal*. 2017;2(1):e35-e46. doi:10.1016/S2468-2667(16)30020-2.
53. Fink VI, Jenkins CA, Castilho JL, Person AK, Shepherd BE, Grinsztejn B, Netto J, Crabtree-Ramirez B, Cortés CP, Padgett D, Jayathilake K, MCGowan C, Cahn P. Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America. *Infect Agents Cancer*. 2018;13(16):1-11. doi:10.1186/s13027-018-0188-3.
54. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy. *Clin Infect Dis*. 2000;30(4 SUPPL. 1). doi:10.1086/313843.
55. Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, Chen YMA, et al. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: Results from the Treat Asia HIV observational database. *J Int AIDS Soc*. 2012;15(1). doi:10.1186/1758-2652-15-1.
56. Garland JM, Levinson A, Wing E. Care of Critically Ill Patients with Human Immunodeficiency Virus. *Ann Am Thorac Soc*. 2020;17(6):659-669. doi:10.1513/AnnalsATS.201909-694CME.
57. Luo B, Sun J, Cai R, Shen Y, Liu L, Wang J, Zhang R, et al. Spectrum of opportunistic infections and risk factors for in-hospital mortality of admitted AIDS patients in Shanghai. *Med (United States)*. 2016;95(21). doi:10.1097/MD.0000000000003802.
58. Clinicalinfo.HIV.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2023. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new>
59. Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B. AIDS e tossicodipendenza: determinanti della sopravvivenza nell'era delle terapie antiretrovirali altamente efficaci. *Epidemiol Prev*. 2009;33(4-5):184-189.

Supplementary file.

Table S1. Comorbidities.

Comorbidities	n (%)
Hypertension	27 (15.6)
Chronic kidney disease	11 (6.4)
Type 2 diabetes	9 (5.2)
Heart failure	6 (3.5)
Chronic obstructive pulmonary disorder	4 (2.3)
Asthma	3 (1.7)




Figure S1. Locations of other neoplasms (non-AIDS-defining neoplasms).